"These staggering numbers mean that we are likely to see large increases in spending on semaglutide and related medications in years to come," said Dhruv S. Kazi, emphasizing the financial implications as more adults become eligible for this treatment.
"Ensuring equitable access to these effective but high-cost medications, as well as supporting individuals so that they can stay on the therapy long-term, should be a priority for our clinicians and policymakers," highlights the importance of addressing healthcare inequities.
The findings presented at the American Heart Association underscore the need to increase equitable access to this new class of pharmaceuticals, which are critical in managing obesity and related health issues.
With approximately 15 million adults currently taking semaglutide, and its potential applications expanding, the drug is likely to have significant implications for healthcare spending and patient care.
Collection
[
|
...
]